Fresh Update,angiotensin II and angiotensin-(1–7

The question of ace inhibitors and arbs target which peptide leads us directly into the intricate workings of the renin-angiotensin-aldosterone system (RAAS). These two classes of medications, ACE inhibitors and ARBs (Angiotensin Receptor Blockers), play crucial roles in managing cardiovascular health, primarily by modulating the effects of a key hormone within this system. At the core of their action is the peptide known as Angiotensin II.

The angiotensin family of peptides is a group of hormones that are vital for regulating blood pressure and fluid balance. The RAAS begins with renin, an enzyme produced by the kidneys. Renin acts on angiotensinogen, a protein produced by the liver, to form angiotensin I. Angiotensin I is then converted into angiotensin II by the Angiotensin-Converting Enzyme (ACE). This conversion process is a critical target for ACE inhibitors.

ACE inhibitors function by preventing the angiotensin-converting enzyme from producing angiotensin II. This reduction in angiotensin II leads to several beneficial effects: blood vessels relax, causing them to widen (vasodilation), which lowers blood pressure. Additionally, it reduces the release of aldosterone, a hormone that promotes sodium and water retention, further contributing to lower blood pressure. The Mayo Clinic notes that ACE inhibitors prevent an enzyme in the body from making angiotensin II, which makes blood vessels narrow, forcing the heart to work harder.

On the other hand, ARBs work slightly differently but achieve a similar outcome. Instead of blocking the production of angiotensin II, ARBs target the receptors where angiotensin II would normally bind, specifically the AGTR1 receptor. By blocking these receptors, ARBs prevent angiotensin II from exerting its effects, such as vasoconstriction and aldosterone release. This also results in lower blood pressure and reduced strain on the cardiovascular system. Consult QD highlights that ARBs prevent angiotensin II from interacting with the AT1R, stopping its vasoconstrictive and aldosterone-stimulating actions.

Therefore, to directly answer the question, ace inhibitors and arbs target which peptide, the primary peptide they influence is angiotensin II. However, the RAAS is complex, and these drugs also indirectly affect other peptides. For instance, the inhibition of angiotensin II can lead to an increase in renin secretion, as noted in research published on PMC. Furthermore, some research suggests that Angiotensin 1–7, another peptide in the system, may have protective effects, and medications like neprilysin are involved in degrading vasoactive peptides including B-type natriuretic peptide and atrial natriuretic peptide.

While ACE inhibitors and ARBs are distinct in their mechanisms, they are often used for similar conditions, including hypertension, chronic renal disease, stroke, and post-myocardial infarction management, as indicated by studies examining their comparative effectiveness and safety. Both drug classes are considered first-line therapy for many cardiovascular conditions. The Johns Hopkins Diabetes Guide mentions that angiotensin II is a potent vasoconstrictor and a negative feedback mediator for renin activity.

In summary, the core peptide targeted by the action of both ACE inhibitors and ARBs is angiotensin II. Understanding this mechanism is key to appreciating how these vital medications help manage a range of serious health conditions. The interplay between these peptides and the enzymes that produce and metabolize them forms the basis of the renin-angiotensin-aldosterone system, a crucial regulatory pathway in the body.